3r7x: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='3r7x' size='340' side='right'caption='[[3r7x]], [[Resolution|resolution]] 2.10Å' scene=''> | <StructureSection load='3r7x' size='340' side='right'caption='[[3r7x]], [[Resolution|resolution]] 2.10Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[3r7x]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/ | <table><tr><td colspan='2'>[[3r7x]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3R7X OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3R7X FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GLU:GLUTAMIC+ACID'>GLU</scene>, <scene name='pdbligand=QSN:N-[6-(1H-IMIDAZOL-1-YL)-7-NITRO-2,4-DIOXO-1,4-DIHYDROQUINAZOLIN-3(2H)-YL]METHANESULFONAMIDE'>QSN</scene | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.1Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GLU:GLUTAMIC+ACID'>GLU</scene>, <scene name='pdbligand=QSN:N-[6-(1H-IMIDAZOL-1-YL)-7-NITRO-2,4-DIOXO-1,4-DIHYDROQUINAZOLIN-3(2H)-YL]METHANESULFONAMIDE'>QSN</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3r7x FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3r7x OCA], [https://pdbe.org/3r7x PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3r7x RCSB], [https://www.ebi.ac.uk/pdbsum/3r7x PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3r7x ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3r7x FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3r7x OCA], [https://pdbe.org/3r7x PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3r7x RCSB], [https://www.ebi.ac.uk/pdbsum/3r7x PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3r7x ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
[https://www.uniprot.org/uniprot/GRIA2_HUMAN GRIA2_HUMAN] Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate.<ref>PMID:20614889</ref> | |||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 26: | Line 26: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Kallen | [[Category: Kallen J]] | ||
Latest revision as of 06:43, 27 November 2024
Crystal Structure Analysis of a Quinazolinedione sulfonamide bound to human GluR2: A Novel Class of Competitive AMPA Receptor Antagonists with Oral Activity
| ||||||||||||
